Feeds › 8-K events
8-K events
Major news companies must report to the SEC: results, deals, leadership changes.
About this data
- What it is
- A Form 8-K is how a public company announces major news between its quarterly reports: earnings, an acquisition, a new CEO, a cybersecurity incident. Each filing lists the numbered items it covers.
- Who files it
- The company, usually within four business days of the event.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Many 8-Ks are routine, so the item description is the place to start. Item 9.01, which only lists attached documents, is hidden unless you ask for it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
8-K items filed per day, last 30 days
All items Earnings results (2.02)
One filing can report several items. Item 9.01, which only lists attached documents, is not counted.
Latest 8-K filings
Showing: ticker NI
| Filed | Company | Item | Form | Filing |
|---|---|---|---|---|
| Nov 9, 2026 | NI NiSource Inc | 8.01 Other Events | 8-K | 8-K ↗ |
| Oct 28, 2026 | NI NiSource Inc | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Oct 16, 2026 | NI NiSource Inc | 2.03 Creation of a Direct Financial Obligation | 8-K | 8-K ↗ |
| Aug 18, 2026 | NI NiSource Inc | 8.01 Other Events | 8-K | 8-K ↗ |
| Aug 5, 2026 | NI NiSource Inc | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| May 18, 2026 | NI NiSource Inc | 8.01 Other Events | 8-K | 8-K ↗ |
| May 12, 2026 | NI NiSource Inc | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| May 6, 2026 | NI NiSource Inc | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Feb 11, 2026 | NI NiSource Inc | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Dec 11, 2025 | NI NiSource Inc | 2.03 Creation of a Direct Financial Obligation | 8-K | 8-K ↗ |
| Dec 11, 2025 | NI NiSource Inc | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Nov 7, 2025 | NI NiSource Inc | 8.01 Other Events | 8-K | 8-K ↗ |
| Oct 31, 2025 | NI NiSource Inc | 8.01 Other Events | 8-K | 8-K ↗ |
| Oct 31, 2025 | NI NiSource Inc | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Oct 29, 2025 | NI NiSource Inc | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Sep 22, 2025 | NI NiSource Inc | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Aug 6, 2025 | NI NiSource Inc | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jun 27, 2025 | NI NiSource Inc | 8.01 Other Events | 8-K | 8-K ↗ |
| May 13, 2025 | NI NiSource Inc | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| May 7, 2025 | NI NiSource Inc | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Mar 27, 2025 | NI NiSource Inc | 8.01 Other Events | 8-K | 8-K ↗ |
| Feb 12, 2025 | NI NiSource Inc | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jan 24, 2025 | NI NiSource Inc | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Oct 30, 2024 | NI NiSource Inc | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
24 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:20 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances